Texas Yale Capital Corp. continued to hold its position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,615 shares of the company’s stock at the end of the second quarter. Texas Yale Capital Corp.’s holdings in Eli Lilly and were worth $1,203,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of LLY. BlackRock Inc. increased its position in Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the period. Vanguard Group Inc. increased its position in Eli Lilly and by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the period. Winslow Capital Management LLC increased its position in Eli Lilly and by 79.7% during the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after buying an additional 1,719,538 shares during the period. Harbour Capital Advisors LLC increased its position in Eli Lilly and by 7,919.1% during the 2nd quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock worth $20,721,000 after buying an additional 1,684,072 shares during the period. Finally, Renaissance Technologies LLC increased its position in Eli Lilly and by 93.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after buying an additional 1,441,200 shares during the period. Hedge funds and other institutional investors own 75.72% of the company’s stock.
In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 990,000 shares of company stock worth $82,949,650 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 86.43 on Friday. The firm has a market capitalization of $91.18 billion, a price-to-earnings ratio of 37.40 and a beta of 0.34. The company has a 50-day moving average price of $83.21 and a 200 day moving average price of $82.21. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 EPS. On average, equities research analysts predict that Eli Lilly and Company will post $4.16 EPS for the current year.
Several research analysts have weighed in on the company. Berenberg Bank reiterated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. cut Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a research report on Wednesday, July 26th. BMO Capital Markets reiterated an “underperform” rating and set a $73.00 price objective on shares of Eli Lilly and in a research report on Wednesday, July 26th. Jefferies Group LLC reiterated a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Finally, Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $93.00 to $90.00 in a research report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $88.57.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.